Skip to main content
SGC $13.03 -0.91%
SGC logo

SGC · Superior Group Of Companies, Inc.

Track SGC — free
$13.03 -0.12 (-0.91%) At close · Aug 14
Market Cap
$207.77M
Shares
15.95M
All earnings calls

Earnings call · FY2026 Q2

Superior Group Of Companies, Inc. Q2 FY2026 Earnings Call

Superior Group Of Companies, Inc. Q2 FY2026 Earnings Call

Concluded Aug 4, 2026 Audio replay
Aug 4, 2026 33:20 39 turns
Period
FY2026 Q2
Runtime
33:20
Sources
4 artifacts

Executive readout · one minute

What matters this quarter

SGC posted Q2 net sales of $147.8 million, up 3% year-over-year, with adjusted diluted EPS of $0.21 more than doubling the prior year, driven by a 27% rise in adjusted EBITDA to $7.7 million, while reaffirming full-year 2026 guidance of $572–$585 million in net sales and $0.54–$0.66 adjusted diluted EPS.

Branded products growth 33 Contact centers recovery 22 Expense management and efficiency 14 Full-year guidance 13 M&A and expansion 11 Healthcare apparel transition 9

Management tone

Positive

Net tone +45 · low hedging

Grounding quotes
  • “We are proud to have delivered a strong quarter with consolidated revenue up 3% year-over-year, a 160 basis point improvement SG&A, EBITDA up 27% to $7.7 million, and adjusted diluted EPS of $0.21, more than doubling the second quarter of 2025.”
  • “our results highlight the benefit of our diversified business as we continue to navigate a choppy demand environment”
  • “we had a strong quarter, and we see clear opportunities ahead for both growth and margin expansion”
  • “The quarter was undeniably challenging, but we view the shorter-term margin pressure and the transition under new leadership as necessary steps towards stronger, more sustainable margins”

Forward guidance

2 guided metrics

Management's latest ranges and targets are included below.

Research coverage

4 live sources

Switch sources without leaving this page or losing your listening position.

Revenue $147.84M +2.6% YoY
Diluted EPS $0.08 -20% YoY
Net income $1.22M -21.3% YoY

Research materials

Open the source you need; every reader stays inside this workspace.

Key takeaways

What improved, and what deserves a closer read.

Constructive signals

  • Adjusted EBITDA rose 27% to $7.7 million from $6.1 million year-ago
  • Adjusted diluted EPS of $0.21 more than doubled the prior year's $0.10
  • SG&A as a percent of sales improved 160 basis points
  • Full-year guidance reiterated above 2025 actuals, with back-half weighted cadence

Risks & pressure points

  • Healthcare apparel revenue declined 4% with gross margin down 260 bps and a $2.6 million inventory write-down
  • Healthcare apparel segment EBITDA declined $1 million year-over-year
  • GAAP net income of $1.2 million included a $2.6 million ($2.0 million after-tax) tradename impairment charge

Key moments

Jump directly to management's words in the synchronized transcript.

Forward guidance

From the 8-K filed Aug 4, 2026.

Metric Guided
Adjusted earnings per diluted share
full-year 2026
$0.54 – $0.66

Guidance from the call

Stated verbally and extracted from the transcript.

Metric Guided
Net sales
2026
$572M – $585M

Quarter detail

How the reported period landed and where the business moved.

Capital returned

Buybacks · derived
$85,000
Shares repurchased
7,353
Dividend / share
$0.14
Full-screen source Call document